公开(公告)号：US20100172902A1

公开(公告)日：2010-07-08

申请号：US12635392

申请日：2009-12-10

申请人： Junho CHUNG ,  Eun Kyung RYU ,  Ji Eun LEE ,  Sukmook LEE

发明人： Junho CHUNG ,  Eun Kyung RYU ,  Ji Eun LEE ,  Sukmook LEE

IPC分类号： A61K39/395 ,  A61P35/00 ,  A61P29/00 ,  A61P37/00 ,  A61P37/06 ,  A61P9/10 ,  A61P1/00

CPC分类号： C07K16/2836 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2319/30

摘要： A method for treating a VCAM-1 mediated disease comprising administering a therapeutically effective amount of a monoclonal antibody to a patient in need thereof. The monoclonal antibody specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1). The monoclonal antibody comprises(a) a light chain CDR 1 region defined by SEQ ID NO:5, a light chain CDR 2 region defined by SEQ ID NO:6, and a light chain CDR 3 region defined by SEQ ID NO:7, and (b) a heavy chain CDR 1 region defined by SEQ ID NO:8, a heavy chain CDR 2 region defined by SEQ ID NO:.9 or 11, and a heavy chain CDR 3 region defined by SEQ ID NO:10 or 12.

摘要翻译： 一种治疗VCAM-1介导的疾病的方法，其包括向有需要的患者施用治疗有效量的单克隆抗体。 单克隆抗体特异性结合人和小鼠血管细胞粘附分子-1（VCAM-1）。 单克隆抗体包含（a）由SEQ ID NO：5定义的轻链CDR1区，由SEQ ID NO：6定义的轻链CDR2区和由SEQ ID NO：7限定的轻链CDR3区， 或（b）由SEQ ID NO：8定义的重链CDR1区域，由SEQ ID NO：.9或11定义的重链CDR2区域和由SEQ ID NO：10定义的重链CDR3区域 12。